<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_raon-2016-0024_s_333_w2aab3b8c39b1b7b1aab1c16b1Aa"><h3>Background</h3><p>The association of HER2 status with urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) levels raises the question whether uPA/PAI-1 level carries additional clinically relevant prognostic information independently from HER2 status. The aim of our study was to compare the prognostic value of uPA/PAI-1 level, HER2 status, and traditional prognostic factors for survival in node-negative breast cancer patients.</p></sec><sec id="j_raon-2016-0024_s_334_w2aab3b8c39b1b7b1aab1c16b2Aa"><h3>Patients and methods</h3><p>A retrospective analysis of 858 node-negative breast cancer patients treated in Maribor University Clinical Center, Slovenia, in the years 2000–2009 was performed. Data were obtained from patient medical records. The median follow-up time was 100 months. Univariate and multivariate analyses of disease-free (DFS) and overall survival (OS) were performed using the Cox regression and the Cox proportional hazards model.</p></sec><sec id="j_raon-2016-0024_s_335_w2aab3b8c39b1b7b1aab1c16b3Aa"><h3>Results</h3><p>In univariate analysis, age, tumor size, grade, lymphovascular invasion, HER2 status and UPA/PAI-1 level were associated with DFS, and age, tumor size, grade, and uPA/PAI-1 level were associated with OS. In the multivariate model, the most important determinants of DFS were age, estrogen receptor status and uPA/PAI-1 level, and the most important factors for OS were patient age and tumor grade. The HR for death from any cause in the multivariate model was 1.98 (95% CI 0.83–4.76) for patients with high uPA and/or PAI-1 compared to patients with both values low.</p></sec><sec id="j_raon-2016-0024_s_336_w2aab3b8c39b1b7b1aab1c16b4Aa"><h3>Conclusions</h3><p>uPA/PAI-1 level clearly carries an independent prognostic value regardless of HER2 status in node-negative breast cancer and could be used in addition to HER2 and other markers to guide clinical decisions in this setting.</p></sec></abstract>

BackgroundThe association of HER2 status with urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) levels raises the question whether uPA/PAI-1 level carries additional clinically relevant prognostic information independently from HER2 status. The aim of our study was to compare the prognostic value of uPA/PAI-1 level, HER2 status, and traditional prognostic factors for survival in node-negative breast cancer patients.Patients and methodsA retrospective analysis of 858 node-negative breast cancer patients treated in Maribor University Clinical Center, Slovenia, in the years 2000–2009 was performed. Data were obtained from patient medical records. The median follow-up time was 100 months. Univariate and multivariate analyses of disease-free (DFS) and overall survival (OS) were performed using the Cox regression and the Cox proportional hazards model.ResultsIn univariate analysis, age, tumor size, grade, lymphovascular invasion, HER2 status and UPA/PAI-1 level were associated with DFS, and age, tumor size, grade, and uPA/PAI-1 level were associated with OS. In the multivariate model, the most important determinants of DFS were age, estrogen receptor status and uPA/PAI-1 level, and the most important factors for OS were patient age and tumor grade. The HR for death from any cause in the multivariate model was 1.98 (95% CI 0.83–4.76) for patients with high uPA and/or PAI-1 compared to patients with both values low.ConclusionsuPA/PAI-1 level clearly carries an independent prognostic value regardless of HER2 status in node-negative breast cancer and could be used in addition to HER2 and other markers to guide clinical decisions in this setting.

Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients

Radiology and Oncology

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

BackgroundThe association of HER2 status with urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) levels raises the question...

Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients

Article Category: Research Article

Pubblicato online: 07 feb 2016

Pagine: 65 - 73

Ricevuto: 13 dic 2015

Accettato: 03 apr 2016

DOI: https://doi.org/10.1515/raon-2016-0024

Parole chiave
node-negative breast cancer, adjuvant systemic treatment, survival, uPA/PAI-1, HER2 status

© 2017 Nina Fokter Dovnik, Iztok Takac

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients

Article Category: Research Article

Pubblicato online: 07 feb 2016

Pagine: 65 - 73

Ricevuto: 13 dic 2015

Accettato: 03 apr 2016

DOI: https://doi.org/10.1515/raon-2016-0024

Parole chiavenode-negative breast cancer, adjuvant systemic treatment, survival, uPA/PAI-1, HER2 status

© 2017 Nina Fokter Dovnik, Iztok Takac

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Parole chiave
node-negative breast cancer, adjuvant systemic treatment, survival, uPA/PAI-1, HER2 status